This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio
by Zacks Equity Research
Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Three Reasons to Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
DexCom (DXCM) Launches Latest CGM Sensor ONE in France
by Zacks Equity Research
DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.
Stryker's (SYK) New Camera Platform to Improve Surgery Outcomes
by Zacks Equity Research
Stryker's (SYK) latest camera platform is likely to enhance the surgical experience across specialties.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Fresenius Medical (FMS) for Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Here's Why You Should Retain Cencora (COR) Stock for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Veeva Systems' (VEEV) New Release to Address Supply-Chain Issues
by Zacks Equity Research
Veeva Systems' (VEEV) new cloud application is likely to improve efficiency and accelerate time-to-market by connecting systems and automating data aggregation, reviews and traceability.
Here's Why You Should Retain DexCom (DXCM) Stock for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
by Zacks Equity Research
OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Stryker (SYK) Gets FDA 501k Clearance for Pangea Trauma Systems
by Zacks Equity Research
Stryker's (SYK) Pangea systems will boost the company's Trauma business unit following a complete launch. SYK plans to present the new system at the Annual Orthopaedic Trauma Association meeting.
Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.
DexCom (DXCM) Rises 7% in One Week: What's Driving It?
by Zacks Equity Research
DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.
Reasons to Retain Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) improving non-medical sales and a solid foothold in the broader MedTech space raise optimism about the stock.
Avantor's (AVTR) Tie-Up to Address Temperature-Specific Logistics
by Zacks Equity Research
Avantor's (AVTR) partnership is likely to meet the growing need among biopharma and life science companies for end-to-end solutions.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Take the Zacks Approach to Beat the Market: Shopify, Novo Nordisk, Amgen in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes
by Zacks Equity Research
BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.
Align Technology's (ALGN) New Feature to Boost Patient Experience
by Zacks Equity Research
Align Technology's (ALGN) introduction of the new SmartForce feature is expected to minimize the number of attachments while maintaining predictable treatment outcomes.
Company News for Sep 7, 2023
by Zacks Equity Research
Companies In The News Are: AVAv, ASND, HQY, PLAB.
Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services
by Zacks Equity Research
Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.